Breakthrough T1D Launches First Global Congress to Accelerate Type 1 Diabetes Cures
Event summary
- Breakthrough T1D (formerly JDRF) hosts inaugural Clinical & Research Congress in Philadelphia from October 9–11, 2026.
- Event gathers 80+ scientific sessions with 16+ countries and dozens of global institutions represented.
- Key focus areas include AI, immune therapies, endocrinologist shortages, and disease-modifying treatments.
- Co-chairs include Dr. Thomas Danne, Dr. Sanjoy Dutta, and Dr. Anastasia Albanese-O'Neill.
The big picture
Breakthrough T1D's inaugural congress marks a strategic pivot toward a more collaborative, interdisciplinary approach to T1D research. As the organization transitions from JDRF, this event underscores its commitment to bridging the gap between scientific discovery and real-world patient care. The focus on emerging technologies and disease-modifying therapies reflects broader industry trends toward precision medicine and digital health solutions.
What we're watching
- Technological Integration
- How AI and digital twin technologies will accelerate T1D research and treatment personalization.
- Regulatory Pathways
- Whether the pace of clinical trials and approvals can match the rapid advancements in T1D therapies.
- Access and Equity
- The extent to which breakthroughs in T1D care will be accessible to all patient populations globally.
